Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.

Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.

Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.

Abstract: Provided are compositions and methods for transducing immune cells in vivo where a viral particle comprising a polynucleotide encoding a chimeric antigen receptor and a multipartite cell-surface receptor is administered to a subject.

Abstract: The present disclosure relates to a vector system comprising at least two polynucleotides, each polynucleotide may comprise a polynucleotide sequence encoding a polypeptide component of a macromolecular complex. Assembly of the macromolecular complex in a cell transduced with the polynucleotides may promote growth and/or survival of a cell.

Abstract: Provided are compositions and methods for transducing immune cells in vivo where a multispecific antibody (e.g. a bispecific T-cell engager) is administered to render immune cells in the subject more transducible by a vector, such as a lentiviral vector.

Abstract: Provided are compositions and methods for polynucleotides and vectors encoding novel chimeric receptor systems. The Gated Adaptor Targeting Receptor (GATR) system employs a dual adaptor system: a first, targeting adaptor and a second, gating adaptor. The targeting adaptor bispecifically binds both the target cell and the gating adaptor, while an engineered cell expressing the chimeric receptor binds the gating adaptor. This targets the engineered cells to an antigen recognized by the targeting adaptor thereby activating the engineered cells and leading to the desired physiological effect.

Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to intravenous or intratumoral injection of a lentiviral particle adapted for transduction and expansion of tumor-infiltrating lymphocytes in vivo.

Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.